Daniyaal Qazi 

Background: Traumatic spinal cord injury (SCI) is a major cause of permanent neurological disability, affecting approximately 20.6 million individuals globally as of 2019, with an annual incidence of 0.9 million new cases.¹ The primary mechanical insult triggers a progressive secondary injury cascade leading to ischemia, glutamate excitotoxicity, oxidative stress, and robust neuroinflammation. This secondary cascade can extend tissue damage several segments beyond the initial injury site.^2,3 Despite advances in early surgical decompression and critical care, no FDA-approved pharmacologic agent specifically targets the molecular drivers of this secondary cascade. Current management remains largely supportive and surgical.^1,2 The NLRP3 inflammasome, a multiprotein complex that activates caspase-1 to drive maturation and release of IL-1β and IL-18, has emerged as a key amplifier of post-injury neuroinflammation and a potential therapeutic target in CNS injury.³

Objective: This narrative review examines the role of the NLRP3 inflammasome in secondary SCI pathophysiology, evaluates pharmacologic and genetic inhibition strategies, and assesses the translational potential of NLRP3-targeted therapy as a bridge between emergent stabilization and molecular neuroprotection.

Search Methods: A literature search was conducted in PubMed using the following MeSH terms and keywords: “NLRP3 inflammasome,” “spinal cord injury,” “secondary injury,” “neuroinflammation,” “MCC950,” “caspase-1,” “IL-1β,” “glutamate excitotoxicity,” and “neuroprotection.” Articles from 2008 to 2025 were included, supplemented by a contemporary epidemiologic registry study (2023).

Results: Jiang et al. (2017) established the temporal profile of NLRP3 activation after SCI in a mouse clip-compression model, demonstrating that NLRP3 mRNA rises within 6 hours, peaks at 72 hours, and declines by day 7. Pharmacologic inhibition with BAY 11-7082 or the P2X7 antagonist A438079 reduced inflammasome components, pro-inflammatory cytokines, microglial and neutrophil infiltration, reactive astrogliosis, and mitochondrial dysfunction, resulting in improved locomotor recovery over 6 weeks, establishing NLRP3 activation as a causal driver of secondary neuroinflammation.⁴ Building on this foundation, Jiao et al. (2020) demonstrated that early systemic administration of MCC950. MCC950 is a potent, selective NLRP3 inhibitor tested in a mouse thoracic contusion model leading to suppression of IL-1β/IL-18 maturation, decreasing lesion volume, and significantly improving locomotor recovery compared to vehicle controls, providing proof-of-concept for selective NLRP3 blockade as an acute neuroprotective strategy.³ Song et al. (2025) identified upstream transcriptional regulation of NLRP3 via a RelA/NLRP3/CCL3 axis: RelA (NF-κB) directly binds the Nlrp3 promoter in microglia, and microglia-specific Nlrp3 conditional knockout or RelA

inhibition with PDTC reduced pyroptosis, immune cell infiltration, and tissue damage, while improving electrophysiologic conduction and locomotor recovery. Exogenous CCL3 partially reversed the previous mentioned benefits, implicating chemokine-mediated immune recruitment as a downstream effector.⁵ Liu et al. (2008) provided mechanistic insight into the convergence of excitotoxicity and inflammasome signaling, showing that post-SCI glutamate elevations drive a caspase-1-dependent reciprocal rise in IL-1β and fall in IL-1ra. Overall, blocking NMDA/AMPA receptors or caspase-1 attenuated this response, and IL-1ra administration improved locomotor recovery, establishing a direct mechanistic link between glutamate receptor activation and inflammasome-mediated cytokine dysregulation.⁶

Conclusion: Collectively, these studies identify NLRP3 as a convergent, mechanistically validated target at the intersection of neuroinflammation and excitotoxicity in traumatic SCI. Pharmacologic inhibition with MCC950-class agents, initiated in the hyperacute phase, represents a promising strategy to limit secondary injury and improve neurological outcomes. While MCC950 itself encountered hepatotoxicity concerns in clinical development for other indications, structurally related inhibitors (i.e. OLT1177 and ZYIL1) are advancing through clinical trials for inflammatory diseases, offering potential translational pathways for SCI. Future research should prioritize defining the optimal therapeutic window, evaluating combinatorial strategies with early decompression, and identifying biomarkers to select patients most likely to benefit from NLRP3-targeted neuroprotection.

Works Cited 

1. GBD Spinal Cord Injuries Collaborators. Global, regional, and national burden of spinal cord injury, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2023 Nov;22(11):1026-1047. doi:10.1016/S1474-4422(23)00287-9. Erratum in: Lancet Neurol. 2024 Apr;23(4):e8. doi: 10.1016/S1474-4422(24)00095-4. PMID: 37863591; PMCID: PMC10584692.
2. Zarmer L, Khan M, Islat G, Alameddin H, Massey M, Chaudhry R. Traumatic Spinal Cord Injury: Review of the Literature. J Clin Med. 2025 May 22;14(11):3649. doi: 10.3390/jcm14113649. PMID: 40507410; PMCID: PMC12155255.
3. Jiao J, Zhao G, Wang Y, Ren P, Wu M. MCC950, a Selective Inhibitor of NLRP3 Inflammasome, Reduces the Inflammatory Response and Improves Neurological Outcomes in Mice Model of Spinal Cord Injury. Front Mol Biosci. 2020 Mar 3;7:37. doi: 10.3389/fmolb.2020.00037. PMID: 32195267; PMCID: PMC7062868.
4. Jiang W, Li M, He F, Zhou S, Zhu L. Targeting the NLRP3 inflammasome to attenuate spinal cord injury in mice. J Neuroinflammation. 2017 Oct 25;14(1):207. doi: 10.1186/s12974-017-0980-9. PMID: 29070054; PMCID: PMC5657095.
5. Song W, Fu R, Yuan Z, Liu Y, Kao Y, Zhang R, Gu G, Zhu H, Liu H, Zhang Z, Kong X, Feng S. Targeting RelA/NLRP3/CCL3 axis mitigates microglia inflammatory response and promotes recovery after spinal cord injury. Brain Behav Immun. 2025 Oct;129:801-817. doi: 10.1016/j.bbi.2025.07.015. Epub 2025 Jul 19. PMID: 40691997.
6. Liu S, Xu GY, Johnson KM, Echetebu C, Ye ZS, Hulsebosch CE, McAdoo DJ. Regulation of interleukin-1beta by the interleukin-1 receptor antagonist in the glutamate-injured spinal cord: endogenous neuroprotection. Brain Res. 2008 Sep 22;1231:63-74. doi: 10.1016/j.brainres.2008.07.035. Epub 2008 Jul 19. PMID: 18675261.